Video Experimental Relacionado
Updated: Sep 10, 2025
09:48
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
8.2K
Ivermectina y cáncer ginecológico: ¿Cuáles son los datos?
Vaidehi Mujumdar1, Marilyn Huang2, Lindsey Chippendale Smith3
1Atrium Health Levine Cancer Institute, 1021 Morehead Drive, Suite 2100, Charlotte, NC 28202, USA.
Gynecologic oncology reports
|August 25, 2025
Resumen
La ivermectina, aprobada para las infecciones parasitarias, carece de datos sobre el tratamiento del cáncer ginecológico. Los investigadores advierten contra su uso en cánceres ginecológicos debido a la evidencia insuficiente de seguridad y eficacia.
Área de la Ciencia:
- Oncología ginecológica
- Farmacología
- Reutilización de las drogas
Sus antecedentes:
- La ivermectina está aprobada por la FDA para el tratamiento de infecciones parasitarias como la loidiasis fuerte y la oncocercosis.
- La investigación existente sobre las propiedades anticancerígenas de la ivermectina se limita principalmente a estudios de líneas celulares in vitro.
- No hay datos completos sobre el potencial de la ivermectina como terapéutico contra el cáncer ginecológico.
Objetivo del estudio:
- Evaluar la base de evidencia actual para el uso de ivermectina en cánceres ginecológicos.
- Identificar las lagunas de conocimiento sobre la seguridad y eficacia de la ivermectina en esta población de pacientes.
- Proporcionar una recomendación clínica sobre la utilidad de la ivermectina en oncología ginecológica.
Principales métodos:
- Revisión de la literatura de los estudios clínicos existentes y de los datos preclínicos sobre la ivermectina en el cáncer.
- Análisis de las indicaciones aprobadas por la FDA para la ivermectina.
- Evaluación de la evidencia disponible específicamente para las aplicaciones de cáncer ginecológico.
Principales resultados:
- No existen datos actuales sobre la eficacia de la ivermectina contra los cánceres ginecológicos.
- Los estudios clínicos que investigan la ivermectina para el tratamiento del cáncer se limitan a las observaciones de líneas celulares.
- No se ha evaluado clínicamente la seguridad y eficacia de la ivermectina en el tratamiento de cánceres ginecológicos.
Conclusiones:
- El uso de ivermectina para el tratamiento de cánceres ginecológicos no está respaldado por la evidencia clínica actual.
- Se recomienda mucha precaución en el uso de ivermectina en el tratamiento de cánceres ginecológicos.
- Se necesitan ensayos clínicos más rigurosos para determinar cualquier papel potencial de la ivermectina en la oncología ginecológica.
Videos de Conceptos Relacionados
01:21Cancer Survival Analysis
453
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
453
01:07Teratogenicity
2.7K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.7K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
01:28Infertility in Females
401
Female infertility is defined as the inability to conceive after a year of regular, unprotected intercourse and affects about 10–15% of couples worldwide. The primary cause of female infertility is ovulatory disorders, which hinder the release of eggs. These disorders can be classified as hypothalamic amenorrhea, polycystic ovarian syndrome (PCOS), premature ovarian failure, and hyperprolactinemic anovulation disorders.
Endometriosis, a condition characterized by abnormal growth of...
Endometriosis, a condition characterized by abnormal growth of...
401
02:49Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K